mcclick
@kyle
The US gov should pay Novo $175B for the Ozempic patent (~12.5x revenue), hold it defensively, and let co’s manufacture/sell it for cheap. Would have a significant impact on annual cost of obesity ($175B) over the next decade and be a positive ROI for the US. And it’d reward Novo for its research and risk.
6 replies
2 recasts
19 reactions
Mm4
@mm4
Lets wait for studies on long term effects of using ozempic for non diabetic people first.
0 reply
0 recast
0 reaction
